XML 28 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment and Geographic Information
 9 Months Ended
Sep. 30, 2018
Segment Reporting [Abstract]  
Segment and Geographic Information
Segment and Geographic Information

The Company manages its business and operations as one segment and is focused on inclisiran as a transformative treatment for ASCVD. The Company allocates resources and assesses financial performance on a consolidated basis. Revenues reported below are derived primarily from sales of Angiomax in the United States.

The geographic segment information provided below is classified based on the major geographic regions in which the Company operates. Long-lived assets are comprised of the Company’s noncurrent assets.

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
 
($ in thousands)
 
 
 
 
 
 
 
 
Net revenues:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
United States
$
(3,213
)
 
97.3
 %
 
$
6,456

 
82.0
%
 
$
5,628

 
91.7
%
 
$
31,426

 
86.8
%
Europe
(88
)
 
2.7
 %
 
1,208

 
15.4
%
 
234

 
3.8
%
 
4,355

 
12.0
%
Rest of world
1

 
—
 %
 
204

 
2.6
%
 
276

 
4.5
%
 
413

 
1.2
%
Total net revenues
$
(3,300
)
 
100
 %
 
$
7,868

 
100
%

$
6,138

 
100.0
%
 
$
36,194

 
100.0
%


 
September 30, 2018
 
December 31, 2017
 
($ in thousands)
Long-lived assets:
 
 
 
 
 
 
 
United States
$
540,866

 
99.0
%
 
$
308,843

 
99.7
%
Europe
5,622

 
1.0
%
 
836

 
0.3
%
Total long-lived assets
$
546,488

 
100.0
%
 
$
309,679

 
100.0
%